Trial
NCT06790303
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Neoplasms
Intervention
Feladilimab
Why stopped
Due to low enrolment of participants
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-06-04